"So these patients did not have much resistance to the experiment of this new drug. After some explanations, they all accepted the new drug experimental project. Immediately, we began to take the drugs according to their condition and conduct
24/7 physical examination.”
While Wu Hao was speaking, a series of relevant data information began to float above his head.
"Everyone, please see, this is the test result one day after taking the medicine, and this is the test result one week later. The following are the test results for one month, two months, and three months respectively." Wu Hao introduced to the crowd.
“Data show that after one day of taking the medicine, more than 85% of the patients had a significant decrease in the gastric Helicobacter pylori carbon-13 breath test values.
After taking the medicine for two days, 98% of the patients had a very significant decrease in the Helicobacter pylori Carbon-13 breath test value. This is the test result after three days of taking the medicine. Basically all the patients had a significant decrease in the Helicobacter pylori Carbon-13 breath test.
The test values have dropped significantly, and some patients’ gastric Helicobacter pylori carbon-13 breath test values have even reached normal values.”
"We immediately conducted gastric testing on the relevant patients and conducted gastric juice and gastric mucosal tissue biopsies, and no signs of Helicobacter pylori were found."
"This is the comprehensive test result after one week of treatment. We can see that 97% of the patients have had Helicobacter pylori carbon-13 breath test values in the stomach reaching normal values, and neither gastric juice nor tissue biopsy has found any
Helicobacter pylori in the stomach. And some patients’ stomachs have been very significantly cured, and many patients with conservative gastric troubles have also gained weight.”
"This is the result of our reexamination one month later. Ninety-nine percent of the patients have fully recovered, all Helicobacter pylori in the stomach has been cleared, and the gastric disease has been cured. Only one percent of the patients, the gastric disease has been cured."
Helicobacter pylori has been significantly suppressed, but the gastric disease has not yet recovered. Two of the patients have the possibility of repeated infection."
"It can be said that this new drug has a very significant and ideal therapeutic effect on Helicobacter pylori in the stomach. Compared with the currently most popular triple and quadruple therapies, it works faster and the full course of treatment is shorter.
Recovery is also faster.
In addition, we also conduct comprehensive monitoring of the patient's body, including the metabolism of our drug in the human body. In particular, many people are worried that this super phage will mutate and persist in the human body. We have conducted strict monitoring.
Data show that after entering the patient's stomach, the super phage in the drug will quickly search for and phagocytose Helicobacter pylori in the stomach. The more Helicobacter pylori in the stomach, the more phagocytosis and division of this super phage will occur. And as time goes by,
With the sharp decrease in the number of Helicobacter pylori in the stomach, these active superphages will begin to lose activity due to the reduction in food, and eventually die.
They will be gradually excreted from the body along with gastrointestinal metabolism. After stopping the drug, the entire metabolic time will be about forty-eight hours, and they will be completely metabolized.
We monitored all patients in the first phase of the clinical trial and found that 80% of the superphages in all patients were completely metabolized within 48 hours after stopping the drug. A few of them had gastrointestinal metabolic disorders, so they were
The metabolism time is slower, but it will be metabolized completely within a week.
No superphages have been detected in any of the patients, nor have any mutations of the superphage virus been found. There have also been no case reports of allergies or side effects due to superphages. Other patients with underlying diseases have not been found either.
Because after taking super phage, the condition worsened."
Speaking of this, Wu Hao smiled at everyone in the audience and said: "At this point, our clinical trial has come to a perfect end. We have achieved very ideal results in this clinical trial, and these data reports further prove that our new
Drug efficacy and safety.
Immediately we applied to start the second phase of clinical trials. This time we expanded the number of patients, not only by cooperating with many domestic hospitals, but also by conducting clinical trials in hospital systems in some overseas countries.
This time, we selected a total of 23,000 patients for phase II clinical trials, including 20,000 domestic patients and 3,000 overseas patients.
And this time, we expanded the scope of testing to all patients suffering from gastric Helicobacter pylori interference, instead of only focusing on severe patients like the first phase.
Therefore, in the second phase clinical trial, we obtained a very rich and massive data information report.
The massive data and information we have obtained from the entire Phase II clinical trial shows that our new drug has a cure rate of 98.7% for gastric Helicobacter pylori infection. All patients participating in the Phase II clinical trial,
No rejection or allergic reactions occurred during the medication period, and there were no reports of any side effects.
All patients metabolized the drug within forty-eight hours to one week after stopping the drug, and no reports were received about the treatment of gastric superphage infection.
It can be said that the entire phase II clinical trial further confirmed the efficacy and safety of our new drug."
"In order to ensure the authenticity of the entire experimental data, we have entrusted domestic and international professional medical data collection institutions with all experimental data collection results, and they are responsible for them. We are not allowed to interfere in the entire process. The entire process is also conducted by relevant departments and expert groups.
Supervision, there is no violation or cheating in the whole process."
While Wu Hao was speaking, relevant report documents were simultaneously displayed above his head, proving to everyone the authenticity of what he said.
After introducing these, Wu Hao breathed a sigh of relief, and then continued: "During the entire testing process, we strictly followed the relevant international new drug clinical trial standards.
In accordance with relevant regulations, we have conducted comprehensive monitoring of the fungal infections that may be caused by this biopharmaceutical. We collected the feces of all patients and conducted laboratory comparisons. All superphages in their feces have been detected.
It has lost its activity and has no ability to infect. This result also further confirms the safety and environmental protection of this new drug."
"Currently, we have stepped up the process of sorting out the phase II clinical trial data, and have started to step up the application and preparation for the larger phase III clinical trial. It is expected that the entire trial period will be about six months, and we will conduct more than five trials across the country.
Hundreds of hospitals are conducting clinical trials, which will cover 100,000 patients this time.
If the experimental results go well, we will immediately start applying for the marketing of this new drug. According to the normal process, it is expected that this new drug will be launched next year."
